Quest Diagnostics has patented a method for detecting specific gene expressions in colonic tumors to identify cancer stem cells and transition zones. The method involves detecting alternating spatial patterns of gene expression to isolate adenoma-adenocarcinoma transition regions. This innovation can aid in diagnosing and predicting invasive transformation of colorectal cancer tumors. GlobalData’s report on Quest Diagnostics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Quest Diagnostics, was a key innovation area identified from patents. Quest Diagnostics's grant share as of May 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Detecting ad-aca transition region in colonic tumor
A recently granted patent (Publication Number: US12000831B2) outlines a method for isolating an adenoma-adenocarcinoma (Ad-ACA) transition region in a colonic tumor. The method involves contacting tissue sections of a colonic tumor sample with specific antibodies targeting PTEN and SMAD4, detecting alternating spatial patterns of expression for these markers, and isolating the Ad-ACA transition region when these patterns are present. The patent also includes the detection of zonal variation in the expression of additional markers such as ALDH1, beta-catenin, CD44, and TP53, among others, to further characterize the transition region.
Furthermore, the patent details a method for isolating the Ad-ACA transition region based on spatial patterns of PTEN and SMAD4 expression in colonic tumor tissue sections. By detecting these patterns and identifying the transition region, the method allows for the precise isolation of this critical area within the tumor. The inverse correlation between the spatial patterns of SMAD4 and PTEN expression is highlighted as a key aspect of the methodology, providing valuable insights into the molecular characteristics of the Ad-ACA transition region in colonic tumors.
To know more about GlobalData’s detailed insights on Quest Diagnostics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
